LBDA

Physician Reference List

These references are to leading research papers on Lewy body dementias and have been recommended by LBDA's Scientific Advisory Council.

BOOK:
O’Brien J, Ames D, McKeith I, Chiu E, eds, “Dementia with Lewy Bodies” Taylor & Francis, 2005, 240 pp.


ARTICLES:

Review

Lippa CF, Duda JE, Grossman M, et al for the DLB/PDD Working Group. “DLB and PDD boundary ssues: diagnosis, treatment, molecular pathology, and biomarkers.” Neurology. 2007 Mar 13;68(11):812-9.

McKeith IG, Dickson DW, Lowe J, et al. “Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.” Neurology. 2005 Dec 27;65(12):1863-72.

McKeith IG (2002) “Dementia with Lewy bodies” British Journal of Psychiatry 180, 144-147

McKeith IG on behalf of IPA Expert Group (2004) “Dementia with Lewy Bodies – a systematic review.” Lancet Neurology 3: 19-28.

McKeith, I. G. (2004). "Dementia with Lewy Bodies (DLB) and other difficult diagnoses." International Psychogeriatrics 16(2): 123 - 127

Biology

Baba M, Nakajo S, Tu PH, et al. "Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.” Am.J Pathol. 1998;152:879-884.

Hansen L, Salmon D, Galasko D, et al. ”The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity.” Neurol. 1990;40:1-8.

Lippa CF, Fujiwara H, Mann DM, et al. “Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes.” Am.J.Pathol. 1998;153:1365-1370

Lippa CF, Smith TW, Perry E. “Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology.” J Neural Transm. 1999;106:525-535.

Perry EK, McKeith I, Thompson P, et al. “Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease.” Ann N Y Acad Sci 1991;640:197-202.

Diagnosis

Aarsland D, Ballard C, Larsen JP, McKeith I. “A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia.” Int J Geriatr Psychiatry 2001;16:528-536.

Aarsland D, Kurz M, Beyer M, Bronnick K, Nore SP, Ballard C. “Early Discriminatory Diagnosis of Dementia with Lewy Bodies: The Emerging Role of CSF and Imaging Biomarkers.” Dement Geriatr Cogn Disord 2008;25:195–205.

Ballard CG, Aarsland D, McKeith I, et al. “Fluctuations in attention: PD dementia vs DLB with parkinsonism.” Neurology 2002;59:1714-1720.

Boeve BF, Silber MH, Ferman TJ, et al. “REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease.” Neurology 1998;51:363-370.

Dubois B, Burn D, Goetz C, Aarsland D, et al. “Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force.” Mov Disord. 2007 Dec;22(16):2314-24.

Kosaka K, Matsushita M, Oyanagi S, Mehraein P. “A cliniconeurophathological study of the Lewy body disease". Seishin Shinkeigaku Zasshi 1980;82:292-311.

McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK. “Operational criteria for senile dementia of Lewy body type (SDLT).” Psychol Med 1992;22:911-922.

McKeith IG, Galasko D, Kosaka K, et al. “Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.” Neurol. 1996;47:1113-1124.

Mosimann UP, Mather G, Wesnes KA, O'Brien JT, Burn DJ, McKeith IG. “Visual perception in Parkinson disease dementia and dementia with Lewy bodies.” Neurology 2004;63:2091-2096.

Orimo S, Amino T, Ozawa E, et al. “A useful marker for differential diagnosis of Parkinson's disease--MIBG myocardial scintigraphy.” Rinsho Shinkeigaku 2004;44:827-829.

Treatment/Management

Barber R, Panikkar A and McKeith IG (2001) “Dementia with Lewy bodies: diagnosis and management.” International Journal of Geriatric Psychiatry 16, S12-S18

Boeve BF, "Dementia with Lewy Bodies" chapter, Dementia Issue, Continuum, American Academy of Neurology, Volume 10, February 2004

Bonelli SB, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M. “L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia.” Neurology 2004;63:376-378.

Burn DJ, McKeith IG. “Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease.” Mov Disord 2003;18 Suppl 6:S72-S79

McKeith IG, Del Ser T, Spano PF, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R and Spiegel R (2000) “Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study” Lancet 356, 2031-2036

Additional Resources:

Boeve BF, Silber MH, Saper CB, et al “Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease.” Brain. 2007 Nov;130(Pt 11):2770-88. Epub 2007 Apr 5.

Boström F, Jönsson L, Minthon L, Londos E. Patients with dementia with lewy bodies have more impaired quality of life than patients with Alzheimer disease.” Alzheimer Dis Assoc Disord. 2007 Apr-Jun;21(2):150-4.

Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. “Dementia and survival in Parkinson disease: a 12-year population study.” Neurology. 2008 Mar 25;70(13):1017-22

Emre M, Aarsland D, Albanese A, et al. “Rivastigmine for dementia associated with Parkinson's disease.” N Engl J Med. 2004 Dec 9;351(24):2509-18.

Duda J, Martine R, “Parkinson's Disease: Mind, Mood and Memory” National Parkinson’s Foundation.

McKeith IG, Rowan E, Askew K, Naidu A, Allan L, Barnett N, Lett D, Mosimann UP, Burn D, O'Brien JT. “More severe functional impairment in dementia with lewy bodies than Alzheimer disease is related to extrapyramidal motor dysfunction.” Am J Geriatr Psychiatry. 2006 Jul;14(7):582-8.

Williams MM, Xiong C, Morris JC, Galvin JE. ”Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease” Neurology. 2006 Dec 12;67(11):1935-41.